NSE
Arvee Laboratories (India) LimitedARVEE
Arvee Laboratories (India) Limited is an Indian pharmaceutical company focused on manufacturing and marketing of APIs and formulations.
| Key products | APIs, Formulations |
|---|---|
| Geography | India |
| Competitors | Dr Reddy's Laboratories, Cipla |
AI-generated overview — verify before relying on it.
Net institutional flow
No institutional deals
Institutional buyers
0 in / 0 out
High-impact filings
0 · tilt Neutral
Next corporate action
—
| # | Company | Inst. flow ₹Cr | Deals | Hi-impact | Filing mom. | Buzz | News |
|---|---|---|---|---|---|---|---|
| 1 | ATALREAL | +₹7.2 Cr | 157 | — | — | — | — |
| 2 | QUADFUTURE | +₹0.1 Cr | 148 | — | — | — | — |
| 3 | MOBIKWIK | +₹0.1 Cr | 83 | — | — | — | — |
| 4 | ARVEEThis | — | — | — | — | — | — |
| 5 | MTNL | +₹0 Cr | 2 | — | — | — | — |
| 6 | GATECH | +₹0 Cr | 8 | — | — | — | — |
| 7 | IRMENERGY | −₹2.2 Cr | 328 | — | — | — | — |
Ranked by net institutional flow (buys − sells, ₹Cr). Filing momentum = bullish − bearish filings; Buzz = news+social sentiment. Curate peers in the company admin.
SWOT
Strengths
- • Strong presence in the Indian pharmaceutical market
- • Diversified product portfolio with a focus on APIs
- • Established partnerships with international clients
- • Growing revenue from formulation business
Weaknesses
- • Dependence on a few key customers
- • Limited presence in the global API market
- • Competition from established players like Dr Reddy's and Cipla
- • Regulatory risks associated with new product approvals
Opportunities
- • Increasing demand for generic APIs due to patent expiries
- • Expansion into emerging markets such as Africa and Southeast Asia
- • Diversification of products through acquisitions or partnerships
- • Growing trend of personalized medicine and targeted therapies
Threats
- • Fluctuations in raw material prices and supply chain disruptions
- • Compliance risks with changing regulatory requirements
- • Intense competition from low-cost producers in India
- • Cybersecurity threats to sensitive data and intellectual property
AI-generated from our data — verify before relying on it.
- 2026-06-15FilingShalin Patel has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and EShareholding Disclosure
Merged from deals, filings, corporate actions and news — newest first. Compact rolls each day up to net flow + counts. Scope with the range above.
Filings that matter
- 2Shareholding DisclosureNeutral
a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Source PDF →
No bulk/block deals for ARVEE in this window.
News & chatter on ARVEE
RSS News
0No recent news.
Google News RSS — links open the source.
Investdesk
0No articles yet.
Our coverage.
No Reddit chatter.
r/ posts mentioning the company.
Twitter / X
0No posts.
Posts mentioning the company.